910023
3,6,9,12,15,18-Hexaoxahexacos-25-ynoic acid
Synonyme(s) :
2-2-2-2-2-2-6 PROTAC® linker, Alkyne-PEG6-acid, Bifunctional linker
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C20H36O8
Poids moléculaire :
404.50
UNSPSC Code:
12352106
Form:
liquid
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderform
liquid
reaction suitability
reagent type: linker
functional group
alkyne, carboxylic acid
storage temp.
2-8°C
SMILES string
OC(COCCOCCOCCOCCOCCOCCCCCCC#C)=O
Application
This heterobifunctional, PEGylated crosslinker 3,6,9,12,15,18-hexaoxahexacos-25-ynoic acid features a carboxyl group at one end and an alkyne at the other and exhibits both hydrophobic and hydrophilic moieties for use in biological applications. This alkyne-PEG6-acid linker can be used for bioconjugation or as a building block for synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds for chemical biology and medicinal chemistry that require ligation. Examples of applications include its synthetic incorporation into antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC® molecules) for targeted protein degradation where the linker region is referred to as 2-2-2-2-2-2-6.
Other Notes
Legal Information
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
Classe de stockage
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Ashton C Lai et al.
Angewandte Chemie (International ed. in English), 55(2), 807-810 (2015-11-26)
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and